menu

ReachMD

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Breakthroughs and Innovations: Managing Complex Cases in Graft-versus-Host Disease

close
4 chapters
Play All
0.50 credits
30 Minutes
Chapter 1
ReachMD Healthcare Image
Restart
Resume
Read full article
Choose a format
Get your free creditsSkip straight to the post-test if you have already participated in this activity
Media formats available:
0.50 credits
A pre-test is required to view this content.
A pre-survey is required to view this content.
Details
Presenters
Related
Comments
  • Overview

    Acute graft-versus-host disease (aGVHD) is a common complication of allogeneic hematopoietic stem cell transplantation and is a major cause of morbidity and mortality. Although systemic corticosteroids are traditional first-line treatment for aGVHD, about half of patients are refractory to therapy. So what options are available for the treatment of steroid-refractory aGVHD?

  • Disclosure of Conflicts of Interest

    Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

    The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

    Name of Faculty or Presenter

    Reported Financial Relationship

    Corey S. Cutler, MD, MPH, FRCPC

    Consultant/Independent Contractor: Janssen, Jazz, Generon, Mesoblast, Syndax. Stock Shareholder: Dana-Farber Cancer Institute.  

    Doris M. Ponce, MD

    Grant/Research Support: Takeda Pharmaceutical. Advisory Board: Kadmon Holdings Inc, Generon.

    Paul P. Doghramji, MD, FAAFP


    Consultant/Independent Contractor: Eisai. Speaker's Bureau: Eisai, Allergan, Novo Nordisk. Advisory Board: Eisai, Allergan. Stock Shareholder: Pfizer, CVS.

    The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: 

    Name of Planner or Manager

    Reported Financial Relationship

    Lindsay Borvansky

    Nothing to disclose

    Andrea Funk

    Nothing to disclose

    Liddy Knight

    Nothing to disclose

    Ashley Cann

    Nothing to disclose

    Chris Washburn, PhD

    Spouse is an employee of Janssen Pharmaceuticals, Inc

    Shirley Jones, MBA

    Nothing to disclose

    Disclosure of Unlabeled Use

    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and Spire Learning LLC do not recommend the use of any agent outside of the labeled indications. 

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

  • Target Audience

    The target audience for this educational initiative will primarily be hematologists, oncologists, oncology nurse practitioners (NPs), and oncology physician assistants (PAs). Clinicians who are involved in the care of patients with GVHD can also participate in the activity as a secondary audience.

  • Learning Objectives

    Upon completion of the program, learners should be better able to:

    • DEVELOP treatment plans for patients with steroid-refractory acute graft-versus-host disease (SR-aGVHD) using novel therapeutic agents

    • SUMMARIZE newly available treatment options for SR-aGVHD

    • DESCRIBE emerging therapies for SR-aGVHD using recent clinical trial data

  • Accreditation and Credit Designation Statements

    Physician Accreditation Statement
    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Spire Learning LLC.  Global is accredited by the ACCME to provide continuing medical education for physicians.

    Physician Credit Designation
    Global Education Group designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Term of Offering
    This activity was released on December 3, 2020 and is valid for one year. Requests for credit must be made no later than December 3, 2021.

    Global Contact Information
    For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

    Instructions to Receive Credit
    In order to receive credit, participant must complete activity and score at least 70% on the posttest, and complete the evaluation.

    Fee Information & Refund/Cancellation Policy
    There is no fee for this educational activity.

  • Provider(s)/Educational Partner(s)

    This activity is jointly provided by Global Education Group and Spire Learning LLC.

    ReachMD Healthcare Image

  • Commercial Support

    This activity is supported by an educational grant from CSL Behring LLC and Incyte Corporation.

  • Disclaimer

    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

  • Spire Learning Privacy Policy

    Spire Learning, LLC is committed to protecting the privacy of personal information from our participants and educational collaborators. Spire maintains physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse, or alteration of personal information.

    Collection and use of your personal information
    The submission of certain personally identifiable information is necessary to award and track the credits participants may earn after completing an activity. Required items include first name, last name, degree, and email address. These items are necessary. Participants are also required to complete an evaluation of each activity. All evaluative information submitted is collected and retained, and used by Spire Learning, LLC to continuously improve the learning experience.

    Spire Learning, LLC will not transfer, sell, or share personal information with outside parties or otherwise disclose personal information unless required to in a legal process. Spire will retain your personal data only for the period necessary to accomplish the stated purposes and to comply with applicable laws.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Related
Comments
  • Overview

    Acute graft-versus-host disease (aGVHD) is a common complication of allogeneic hematopoietic stem cell transplantation and is a major cause of morbidity and mortality. Although systemic corticosteroids are traditional first-line treatment for aGVHD, about half of patients are refractory to therapy. So what options are available for the treatment of steroid-refractory aGVHD?

  • Disclosure of Conflicts of Interest

    Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

    The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

    Name of Faculty or Presenter

    Reported Financial Relationship

    Corey S. Cutler, MD, MPH, FRCPC

    Consultant/Independent Contractor: Janssen, Jazz, Generon, Mesoblast, Syndax. Stock Shareholder: Dana-Farber Cancer Institute.  

    Doris M. Ponce, MD

    Grant/Research Support: Takeda Pharmaceutical. Advisory Board: Kadmon Holdings Inc, Generon.

    Paul P. Doghramji, MD, FAAFP


    Consultant/Independent Contractor: Eisai. Speaker's Bureau: Eisai, Allergan, Novo Nordisk. Advisory Board: Eisai, Allergan. Stock Shareholder: Pfizer, CVS.

    The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: 

    Name of Planner or Manager

    Reported Financial Relationship

    Lindsay Borvansky

    Nothing to disclose

    Andrea Funk

    Nothing to disclose

    Liddy Knight

    Nothing to disclose

    Ashley Cann

    Nothing to disclose

    Chris Washburn, PhD

    Spouse is an employee of Janssen Pharmaceuticals, Inc

    Shirley Jones, MBA

    Nothing to disclose

    Disclosure of Unlabeled Use

    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and Spire Learning LLC do not recommend the use of any agent outside of the labeled indications. 

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

  • Target Audience

    The target audience for this educational initiative will primarily be hematologists, oncologists, oncology nurse practitioners (NPs), and oncology physician assistants (PAs). Clinicians who are involved in the care of patients with GVHD can also participate in the activity as a secondary audience.

  • Learning Objectives

    Upon completion of the program, learners should be better able to:

    • DEVELOP treatment plans for patients with steroid-refractory acute graft-versus-host disease (SR-aGVHD) using novel therapeutic agents

    • SUMMARIZE newly available treatment options for SR-aGVHD

    • DESCRIBE emerging therapies for SR-aGVHD using recent clinical trial data

  • Accreditation and Credit Designation Statements

    Physician Accreditation Statement
    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Spire Learning LLC.  Global is accredited by the ACCME to provide continuing medical education for physicians.

    Physician Credit Designation
    Global Education Group designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Term of Offering
    This activity was released on December 3, 2020 and is valid for one year. Requests for credit must be made no later than December 3, 2021.

    Global Contact Information
    For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

    Instructions to Receive Credit
    In order to receive credit, participant must complete activity and score at least 70% on the posttest, and complete the evaluation.

    Fee Information & Refund/Cancellation Policy
    There is no fee for this educational activity.

  • Provider(s)/Educational Partner(s)

    This activity is jointly provided by Global Education Group and Spire Learning LLC.

    ReachMD Healthcare Image

  • Commercial Support

    This activity is supported by an educational grant from CSL Behring LLC and Incyte Corporation.

  • Disclaimer

    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

  • Spire Learning Privacy Policy

    Spire Learning, LLC is committed to protecting the privacy of personal information from our participants and educational collaborators. Spire maintains physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse, or alteration of personal information.

    Collection and use of your personal information
    The submission of certain personally identifiable information is necessary to award and track the credits participants may earn after completing an activity. Required items include first name, last name, degree, and email address. These items are necessary. Participants are also required to complete an evaluation of each activity. All evaluative information submitted is collected and retained, and used by Spire Learning, LLC to continuously improve the learning experience.

    Spire Learning, LLC will not transfer, sell, or share personal information with outside parties or otherwise disclose personal information unless required to in a legal process. Spire will retain your personal data only for the period necessary to accomplish the stated purposes and to comply with applicable laws.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule19 Oct 2021